lunes, 28 de octubre de 2019

Axovant CEO David Hung is back — leading a cancer biotech - STAT

Axovant CEO David Hung is back — leading a cancer biotech - STAT

Daily Recap

STAT Plus: Former Axovant CEO David Hung is back — leading a cancer biotech with hefty funding

By KATE SHERIDAN


PHOTO ILLUSTRATION: STAT, PHOTO: HANDOUT
Hung is best known for founding Medivation — which developed Xtandi, a drug for prostate cancer — and then selling the company to Pfizer for $14 billion.

No hay comentarios: